Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;112(5):701-713.
doi: 10.1111/ejh.14161. Epub 2023 Dec 25.

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain

Moritz Lehne  1 , K Martin Kortüm  2 , Karthik Ramasamy  3 , Elena Zamagni  4 , Tim d'Estrubé  5 , Evi Zhuleku  1 , Maya Hanna  6 , Soham Shukla  6 , Marco Ghiani  7 , Ulf Maywald  8 , Thomas Wilke  7 , Lenka Kellermann  9 , Sue Perera  5
Affiliations

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain

Moritz Lehne et al. Eur J Haematol. 2024 May.

Abstract

Objectives: To retrospectively analyze real-world treatment patterns in patients with relapsed/refractory multiple myeloma (RRMM) who initiated third-line treatment in Europe.

Methods: German and Italian administrative claims data were sourced from the German AOK PLUS health insurance fund and Italian local health units (2016-2020). Data for the United Kingdom (UK), France, and Spain were sourced from medical chart reviews (MCRs) from 2016 to 2018 (historical) and 2019 to 2021 (new) using electronic case report forms.

Results: Across all countries, immunomodulatory imide drug (IMiD)-based regimens were prominent in the third-line setting. From 2016 to 2020, lenalidomide-dexamethasone was most common in Italy (18.0%) and Germany (12.7%). From 2019 to 2021, the most common regimen was ixazomib-lenalidomide-dexamethasone (67.5%) in the UK, pomalidomide-dexamethasone (17.1%) in France, and daratumumab-bortezomib-dexamethasone (15.0%) in Spain. In the historical data (2016-2018), third-line lenalidomide- and pomalidomide-dexamethasone doublet use across the UK (>47%), France (>46%), and Spain (>33%) was high. From historical to new, triplet use increased in Spain (>19% to >60%) as did anti-CD38 agent use in France (15.1% to 51.9%) and Spain (19.7% to 42.1%).

Conclusions: From 2016 to 2021, third-line regimens were mostly IMiD based. The MCR data demonstrated evolving treatment choices from 2016 to 2018 and 2019 to 2021, providing insights into uptake of novel agents and current RRMM European clinical practice.

Keywords: Europe; costs; health outcomes; healthcare resource utilization; multiple myeloma; relapsed/refractory; third‐line treatment patterns; treatment outcomes; treatment sequence.

PubMed Disclaimer

References

REFERENCES

    1. Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221‐1227.
    1. Goldschmidt N, Zamir L, Poperno A, Kahan NR, Paltiel O. Presenting signs of multiple myeloma and the effect of diagnostic delay on the prognosis. J Am Board Fam Med. 2016;29(6):702‐709.
    1. Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta‐analysis. Eur J Haematol. 2016;97(5):416‐429.
    1. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA‐ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32(3):309‐322.
    1. Dhanasiri S, Hollier‐Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez‐Otero P. Treatment patterns and outcomes in triple‐class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study. Clin Ther. 2021;43(11):1983‐1996.e1983.

MeSH terms

Grants and funding